Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models

Leslie Muldoon, Seymur Gahramanov, Xin Li, Deborah J. Marshall, Dale Kraemer, Edward Neuwelt

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We used dynamic MRI to evaluate the effects of monoclonal antibodies targeting brain tumor vasculature. Female athymic rats with intracerebral human tumor xenografts were untreated or treated with intetumumab, targeting aV-integrins, or bevacizumab, targeting vascular endothelial growth factor (n = 4-6 per group). Prior to treatment and at 1, 3, and 7 days after treatment, we performed standard MRI to assess tumor volume, dynamic susceptibility-contrast MRI with the blood-pool iron oxide nanoparticle ferumoxytol to evaluate relative cerebral blood volume (rCBV), and dynamic contrast-enhanced MRI to assess tumor vascular permeability. Tumor rCBV increased by 27 ± 13% over 7 days in untreated rats; intetumumab increased tumor rCBV by 65±10%, whereas bevacizumab reduced tumor rCBV by 31 ±10% at 7 days (P v-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy.

Original languageEnglish (US)
Pages (from-to)51-60
Number of pages10
JournalNeuro-Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Blood Vessels
Magnetic Resonance Imaging
Neoplasms
Capillary Permeability
Integrins
Nude Rats
Ferrosoferric Oxide
Blood Volume
Tumor Burden
Heterografts
Brain Neoplasms
Nanoparticles
Vascular Endothelial Growth Factor A
Monoclonal Antibodies
Drug Therapy
Cerebral Blood Volume
Therapeutics
Bevacizumab
intetumumab

Keywords

  • Bevacizumab
  • Blood-brain barrier
  • Dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging
  • Intetumumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. / Muldoon, Leslie; Gahramanov, Seymur; Li, Xin; Marshall, Deborah J.; Kraemer, Dale; Neuwelt, Edward.

In: Neuro-Oncology, Vol. 13, No. 1, 01.2011, p. 51-60.

Research output: Contribution to journalArticle

@article{d1e70c967af8425289a270751df8a44e,
title = "Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models",
abstract = "We used dynamic MRI to evaluate the effects of monoclonal antibodies targeting brain tumor vasculature. Female athymic rats with intracerebral human tumor xenografts were untreated or treated with intetumumab, targeting aV-integrins, or bevacizumab, targeting vascular endothelial growth factor (n = 4-6 per group). Prior to treatment and at 1, 3, and 7 days after treatment, we performed standard MRI to assess tumor volume, dynamic susceptibility-contrast MRI with the blood-pool iron oxide nanoparticle ferumoxytol to evaluate relative cerebral blood volume (rCBV), and dynamic contrast-enhanced MRI to assess tumor vascular permeability. Tumor rCBV increased by 27 ± 13{\%} over 7 days in untreated rats; intetumumab increased tumor rCBV by 65±10{\%}, whereas bevacizumab reduced tumor rCBV by 31 ±10{\%} at 7 days (P v-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy.",
keywords = "Bevacizumab, Blood-brain barrier, Dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging, Intetumumab",
author = "Leslie Muldoon and Seymur Gahramanov and Xin Li and Marshall, {Deborah J.} and Dale Kraemer and Edward Neuwelt",
year = "2011",
month = "1",
doi = "10.1093/neuonc/noq150",
language = "English (US)",
volume = "13",
pages = "51--60",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models

AU - Muldoon, Leslie

AU - Gahramanov, Seymur

AU - Li, Xin

AU - Marshall, Deborah J.

AU - Kraemer, Dale

AU - Neuwelt, Edward

PY - 2011/1

Y1 - 2011/1

N2 - We used dynamic MRI to evaluate the effects of monoclonal antibodies targeting brain tumor vasculature. Female athymic rats with intracerebral human tumor xenografts were untreated or treated with intetumumab, targeting aV-integrins, or bevacizumab, targeting vascular endothelial growth factor (n = 4-6 per group). Prior to treatment and at 1, 3, and 7 days after treatment, we performed standard MRI to assess tumor volume, dynamic susceptibility-contrast MRI with the blood-pool iron oxide nanoparticle ferumoxytol to evaluate relative cerebral blood volume (rCBV), and dynamic contrast-enhanced MRI to assess tumor vascular permeability. Tumor rCBV increased by 27 ± 13% over 7 days in untreated rats; intetumumab increased tumor rCBV by 65±10%, whereas bevacizumab reduced tumor rCBV by 31 ±10% at 7 days (P v-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy.

AB - We used dynamic MRI to evaluate the effects of monoclonal antibodies targeting brain tumor vasculature. Female athymic rats with intracerebral human tumor xenografts were untreated or treated with intetumumab, targeting aV-integrins, or bevacizumab, targeting vascular endothelial growth factor (n = 4-6 per group). Prior to treatment and at 1, 3, and 7 days after treatment, we performed standard MRI to assess tumor volume, dynamic susceptibility-contrast MRI with the blood-pool iron oxide nanoparticle ferumoxytol to evaluate relative cerebral blood volume (rCBV), and dynamic contrast-enhanced MRI to assess tumor vascular permeability. Tumor rCBV increased by 27 ± 13% over 7 days in untreated rats; intetumumab increased tumor rCBV by 65±10%, whereas bevacizumab reduced tumor rCBV by 31 ±10% at 7 days (P v-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy.

KW - Bevacizumab

KW - Blood-brain barrier

KW - Dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging

KW - Intetumumab

UR - http://www.scopus.com/inward/record.url?scp=79951610184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951610184&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq150

DO - 10.1093/neuonc/noq150

M3 - Article

C2 - 21123368

AN - SCOPUS:79951610184

VL - 13

SP - 51

EP - 60

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -